Peptides for ADHD and autism: what the evidence actually shows
Quick answer
Semax (a synthetic ACTH analog) and Selank (a synthetic tuftsin analog) have demonstrated dopaminergic and GABAergic activity in preclinical and limited Russian clinical research, but neither has been evaluated in peer-reviewed human trials specifically for ADHD. The creator's dosing recommendation of 500 micrograms of Semax up to three times daily is drawn from anecdotal and compounding pharmacy sources, not from controlled clinical evidence. Patients considering these compounds should consult a licensed clinician, as neither peptide is FDA-approved and sourcing through unregulated channels carries meaningful quality and safety risks.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @daviddemesquita actually say?
The creator pitched two peptides, which he calls "C-Max" and "Salient" (almost certainly Semax and Selank), as alternatives to stimulant medications for ADHD and ADD. His core argument: stimulants blast you with dopamine, raise your heart rate, and crank up anxiety. Semax, he says, "drives up dopamine" for cognitive focus, while Selank "drives up GABA" to calm you down. He also name-dropped BDNF, claimed stimulants suppress it, and said resistance training and Semax can restore it. He finished with a reference to stroke research. Dosing was mentioned explicitly: 500 micrograms of Semax, up to two to three times per day.
That last part is worth flagging immediately. Recommending specific dosing protocols for unapproved research compounds to a general TikTok audience is irresponsible, and this fact-check will not repeat or endorse those numbers as clinical guidance.
Does the science back this up?
Partially, but the gap between "there is research" and "this will change your world" is enormous, and the creator blurs that line throughout. Semax is a synthetic analog of ACTH(4-7) developed in Russia, where it has been studied and is actually approved for neurological conditions including stroke recovery. Selank is similarly a Russian-developed synthetic peptide based on tuftsin. Neither is FDA-approved in the United States.
On Semax and BDNF: there is real animal data here. Dolotov et al. (2006, Journal of Neurochemistry) found Semax increased BDNF and its receptor TrkB in rat brain tissue. That is not nothing. On Selank and GABA: a 2007 study by Semenova et al. (Bulletin of Experimental Biology and Medicine) found Selank modulated GABAergic transmission in rats. Again, animal data. Human clinical trials for either compound specifically targeting ADHD symptoms essentially do not exist in peer-reviewed Western literature. The creator is extrapolating from mechanism to clinical outcome across a very wide and largely unstudied gap.
What did they get wrong (or right)?
Credit where it is due: the point about BDNF suppression from chronic stimulant use is a legitimate area of scientific discussion, though the evidence is mixed and context-dependent. The connection between resistance training and BDNF elevation is genuinely well-supported. Szuhany et al. (2015, Journal of Psychiatric Research) conducted a meta-analysis confirming exercise robustly increases BDNF levels. That part of the video is actually solid.
What is wrong, or at least badly overstated: calling Semax and Selank "natural" peptides is misleading. Semax is a synthetic heptapeptide. It does not occur naturally in the human body. Selank is a synthetic analog. The word "natural" in this context appears designed to contrast with pharmaceuticals in a way that implies safety, and that implication is not earned by the evidence. The creator also frames stimulant medications as simply "blasting" the brain, which flattens a complex pharmacological picture and could discourage people from evidence-based treatment. That is the most consequential problem with this video.
What should you actually know?
Semax and Selank are genuinely interesting research compounds with plausible mechanisms. The science is not made up. But "interesting mechanism in rodents" and "proven treatment for ADHD" are not the same category, and this video regularly treats them as if they are. There are no randomized controlled trials of Semax or Selank for ADHD in humans published in peer-reviewed English-language journals as of this writing.
In the United States, both compounds exist in a regulatory gray zone, often sold as research chemicals or compounded by pharmacies operating outside standard FDA oversight. Quality control is a real concern. You cannot verify purity or concentration the way you can with an FDA-approved medication.
If you have ADHD and are curious about adjunct approaches, the resistance training recommendation here is the one thing backed by solid human data. Everything else in this video requires a conversation with a physician who actually knows your history, not a TikTok dosing suggestion.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 5 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Peptides for ADHD and autism: what the evidence actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Functional Connectomic Approach to Studying Selank and Semax Effects
Small Russian fMRI study (52 healthy volunteers) of brain connectivity after Semax or Selank; mechanistic and exploratory, not a clinical efficacy trial.
PubMed
Effects of Semax on the Default Mode Network of the Brain
Small human fMRI study (24 adults) of intranasal Semax on brain networks; an imaging-marker study with no clinical outcomes, not replicated outside the originating group.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Peptides for ADHD and autism: what the evidence actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Semax (a synthetic ACTH analog) and Selank (a synthetic tuftsin analog) have demonstrated dopaminergic and GABAergic activity in preclinical and limited Russian clinical research, but neither has been evaluated in peer-reviewed human trials specifically for ADHD.
FormBlends verdict
Semax (a synthetic ACTH analog) and Selank (a synthetic tuftsin analog) have demonstrated dopaminergic and GABAergic activity in preclinical and limited Russian clinical research, but neither has been evaluated in peer-reviewed human trials specifically for ADHD. The creator's dosing recommendation of 500 micrograms of Semax up to three times daily is drawn from anecdotal and compounding pharmacy sources, not from controlled clinical evidence. Patients considering these compounds should consult a licensed clinician, as neither peptide is FDA-approved and sourcing through unregulated channels carries meaningful quality and safety risks.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semax (a synthetic ACTH analog) and Selank (a synthetic tuftsin analog) have demonstrated dopaminergic and GABAergic activity in preclinical and limited Russian clinical research, but neither has been evaluated in peer-reviewed human trials specifically for ADHD. The creator's dosing recommendation of 500 micrograms of Semax up to three times daily is drawn from anecdotal and compounding pharmacy sources, not from controlled clinical evidence. Patients considering these compounds should consult a licensed clinician, as neither peptide is FDA-approved and sourcing through unregulated channels carries meaningful quality and safety risks.
- Semax and Selank are synthetic peptides developed in Russia, not naturally occurring compounds. Calling them 'natural' is inaccurate and implies an unearned safety profile.
- No peer-reviewed, randomized controlled trials exist evaluating Semax or Selank specifically for ADHD in human populations as of current literature.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Semax and Selank are synthetic peptides developed in Russia, not naturally occurring compounds. Calling them 'natural' is inaccurate and implies an unearned safety profile.
- No peer-reviewed, randomized controlled trials exist evaluating Semax or Selank specifically for ADHD in human populations as of current literature.
- Dolotov et al. (2006, Journal of Neurochemistry) confirmed Semax increases BDNF in rat brain tissue, which is real data, but animal mechanism studies do not establish human clinical benefit.
- Szuhany et al. (2015, Journal of Psychiatric Research) meta-analyzed 29 studies and found exercise robustly elevates BDNF. The resistance training recommendation in this video is the most evidence-backed suggestion it makes.
- Neither Semax nor Selank is FDA-approved, and both are commonly sourced through compounding pharmacies or research chemical suppliers where purity and concentration are not independently verified.
- Specific dosing recommendations for unapproved research compounds shared on social media are not clinical guidance and should not be followed without evaluation by a licensed physician.
- Framing stimulant medications as simply 'blasting' the brain may discourage people from evidence-based ADHD treatment. Stimulants remain the most extensively studied and clinically validated pharmacological option for ADHD.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
David DeMesquita™️ · TikTok creator
41.0K views on this video
#ADHD and #ADD has alternative solutions people are not talking about #autism #autismawareness
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by David DeMesquita™️, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.